Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.
The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry.
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
Definition of the viral targets of protective HIV-1-specific T cell responses.
Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
A therapeutic dendritic cell-based vaccine for HIV-1 infection.
Impact of phenotype definition on genome-wide association signals: empirical evaluation in human immunodeficiency virus type 1 infection.